CN Patent

CN113423404B — 一种黄嘌呤衍生物药物组合物及其制备方法

Assigned to Chengdu Easton Biopharmaceuticals Co Ltd · Expires 2023-09-29 · 3y expired

What this patent protects

本发明提供了一种黄嘌呤衍生物药物组合物，具体而言，提供了一种黄嘌呤衍生物的药物组合物及其制备方法及其作为治疗药物，特别是作为治疗二肽基肽酶(DPP‑IV)抑制剂的用途。

USPTO Abstract

本发明提供了一种黄嘌呤衍生物药物组合物，具体而言，提供了一种黄嘌呤衍生物的药物组合物及其制备方法及其作为治疗药物，特别是作为治疗二肽基肽酶(DPP‑IV)抑制剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN113423404B
Jurisdiction
CN
Classification
—
Expires
2023-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Easton Biopharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.